Please login to the form below

Not currently logged in
Email:
Password:

LCZ696

This page shows the latest LCZ696 news and features for those working in and with pharma, biotech and healthcare.

Novartis' Entresto launched in UK

Novartis' Entresto launched in UK

The results of the PARADIGM-HF study showed that patients treated with LCZ696 were 20% less likely to die from a cardiovascular cause or hospitalisation and were also 16% less likely

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics